VST Bio Corporation is pioneering a new class of therapeutics aimed at controlling vascular permeability, particularly in the context of acute ischemic stroke and myocardial infarction. The company has developed first-in-class humanized antibodies that target novel pathways involved in regulating vascular leakage, a significant co-morbidity in various diseases. Their proprietary technology focuses on blocking inflammation- and injury-induced vascular leaks without disrupting normal vascular function. Preclinical studies in rodent and non-human primate models have demonstrated that a single intravenous bolus of their antibodies can significantly reduce cerebral damage—by up to 80%—even when administered late after the onset of stroke symptoms. This innovative approach addresses the critical need for effective therapies in acute cardiovascular events, where traditional treatments are often ineffective after a few hours.

VST Bio's lead product, VST-201, is designed to normalize vascular dysfunction and mitigate ongoing tissue damage caused by edema, inflammation, and oxidative stress in ischemic stroke patients. The therapy can be administered within days of symptom onset, offering a new treatment avenue for patients who miss the window for conventional therapies. The company has received significant funding to advance this promising therapy, which has shown a favorable safety profile in animal models. With a robust intellectual property portfolio, VST Bio is well-positioned to make a substantial impact in the field of cardiovascular medicine, aiming to improve patient outcomes and accelerate recovery from acute ischemic events.

United States

VST-Bio’s team envisions a future where ischemic stroke and myocardial infraction no longer impose a life-threatening tissue damage or progression to neurological dysfunction or heart failure. 

VST Bio Corporation

Company Details